Streetbeat News

Revenues

OMC

In the last three months, 5 analysts have updated their ratings on Omnicom Group (NYSE:OMC), showing a mix of bullish and indifferent stances. The average 12-month price target has risen to $104.6, marking a 20.69% increase from the previous target. Analysts from firms like Exane BNP Paribas, Wells Fargo, Barclays, UBS, and Macquarie have adjusted their ratings and price targets, reflecting a positive outlook on OMC's performance. Omnicom's financials show strong revenue growth, net margin, ROE, and ROA, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 1:00 pm

REBN

Reborn Coffee reported a significant increase in its Q4 2023 revenue, reaching $1.9M, up from $900K in the same quarter the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:50 pm

SPY

UUP

U.S. GDP growth for Q4 2023 was revised up to 3.4%, indicating solid economic activity despite a deceleration from the previous quarter's 4.9%. The revision was due to increased consumer spending and government investment, offset by lower private inventory and exports. Meanwhile, jobless claims were lower than expected, suggesting a strong labor market. The U.S. dollar strengthened following Fed remarks, impacting the Invesco DB USD Index Bullish Fund ETF (UUP), while the SPDR S&P 500 ETF Trust (SPY) reached a record high.

Portfolio Pulse from Piero Cingari

March 28, 2024 | 12:46 pm

TAYD

Taylor Devices reported a significant increase in its Q3 2024 earnings per share (EPS) to $0.82 from $0.47 year-over-year (YoY). Sales also rose to $12.254 million from $9.891 million YoY.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:40 pm

SPY

The US GDP for Q4 showed a growth of 3.4%, surpassing the estimated 3.2%. This indicates a stronger than expected economic performance.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:30 pm

PMD

Psychemedics Corp reported a decrease in FY23 revenue to $22.1M from $25.2M year-over-year, with an increased EPS loss of $(0.72) compared to $(0.19) YoY. The company's cash balance stood at $2.0M.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:24 pm

DARE

Daré Bioscience reported its FY23 financial results, with a revenue of $2.8M surpassing the $2.07M estimate. The EPS loss was $(0.35), better than the $(0.38) estimate. The company also reported a cash balance of $10.5M.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:11 pm

SYRA

Syra Health Corp. (NASDAQ:SYRA) has secured a statewide healthcare workforce contract in Missouri to provide temporary medical services personnel. The contract's revenue will depend on the number of positions filled and their duration, focusing on recruiting specialized medical professionals like resident physicians, physicians, chief physicians, psychiatrists, and chief psychiatrists. This expansion into Missouri marks the 18th state where Syra Health has established a presence, emphasizing its commitment to enhancing healthcare delivery nationwide.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:11 pm

BWAY

BrainsWay announced the publication of post-marketing analysis results on late-life depression in the Journal of Clinical Medicine. The study likely showcases the effectiveness of BrainsWay's technology in treating this condition, which could influence the company's reputation and potentially its financial performance.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:10 pm

IMNN

Imunon announced that its current financial assets totaling $15.7M, along with future planned sales of its remaining $1.3M New Jersey NOLS, are expected to extend its cash runway into Q4 2024. This update provides insights into the company's financial health and future funding strategy.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 12:07 pm